GS-US-218-0108, “A Phase 2b, Randomized, Double-Blind, A Phase 2b, Randomized, Double-Blind, Placebo Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS 5806 in Hematopoietic Cell Transplant (HCT) R

Project: Research project

Project Details

StatusFinished
Effective start/end date3/24/153/24/18

Funding

  • Duke Clinical Research Institute (GS-US-218-0108)
  • Gilead Sciences, Inc. (GS-US-218-0108)